Provectus Biopharmaceuticals Management
Management criteria checks 4/4
Provectus Biopharmaceuticals' CEO is Ed Pershing, appointed in Apr 2024, has a tenure of less than a year. directly owns 4.39% of the company’s shares, worth $2.07M. The average tenure of the management team and the board of directors is 3.3 years and 5.5 years respectively.
Key information
Ed Pershing
Chief executive officer
US$75.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 4.4% |
| Management average tenure | 3.3yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
CEO
Ed Pershing (71 yo)
less than a year
Tenure
US$75,000
Compensation
Mr. Edward V. Pershing, also known as Ed, CPA has been Chairman of Provectus Biopharmaceuticals, Inc., since April 27, 2018 and serves as its Chief Executive Officer since April 2024. He served as the Chie...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of Board | less than a year | US$75.00k | 4.39% $ 2.1m | |
| President & Vice Chairman of the Board | 7.8yrs | US$75.00k | 0.26% $ 120.8k | |
| Co-Founder & CTO | 12.7yrs | US$253.25k | 1.58% $ 745.4k | |
| Chief Financial Officer | 5.8yrs | US$125.00k | 0.29% $ 136.0k |
3.3yrs
Average Tenure
59yo
Average Age
Experienced Management: PVCT's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of Board | 6.8yrs | US$75.00k | 4.39% $ 2.1m | |
| President & Vice Chairman of the Board | 7.8yrs | US$75.00k | 0.26% $ 120.8k | |
| Member of Strategic Advisory Board | 5.5yrs | no data | no data | |
| Chairman of Strategic Advisory Board & Independent Director | 6.8yrs | US$80.00k | 0.048% $ 22.4k | |
| Member of Scientific Advisory Board | 5.3yrs | no data | no data | |
| Independent Director | 5yrs | US$80.00k | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data |
5.5yrs
Average Tenure
63yo
Average Age
Experienced Board: PVCT's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 12:02 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Provectus Biopharmaceuticals, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anthony Vendetti | Maxim Group |
| I-Eh Jen | Maxim Group |
| Ricky Snyder | Maxim Group |